Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
21.87 USD -6.10% Intraday chart for Arrowhead Pharmaceuticals, Inc. -3.27% -28.53%
Apr. 24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease CI
Apr. 07 Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo CI

Business Summary

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Number of employees: 525

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Drugs
100.0 %
243 100.0 % 241 100.0 % -1.03%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
243 100.0 % 241 100.0 % -1.03%

Managers

Managers TitleAgeSince
Christopher Anzalone CEO
 Chief Executive Officer 54 07-11-30
Kenneth Myszkowski DFI
 Director of Finance/CFO 57 08-12-31
Peter Carignan CTO
 Chief Tech/Sci/R&D Officer - 22-07-31
Patrick O'brien CMP
 Compliance Officer 60 14-11-30
Bruce Given COO
 Chief Operating Officer 69 11-10-25
Vincent Anzalone IRC
 Investor Relations Contact - -
Aaron Tan AUD
 Comptroller/Controller/Auditor - 21-06-30
Nadia Meshkova TRE
 Treasurer - -
Tracie Oliver PRN
 Corporate Officer/Principal 62 22-05-31
Matt Pulisic PRN
 Corporate Officer/Principal - 20-07-31

Members of the board

Members of the board TitleAgeSince
Douglass Given CHM
 Chairman 71 10-11-22
Michael Perry BRD
 Director/Board Member 64 11-12-18
Adeoye Olukotun BRD
 Director/Board Member 79 20-08-31
Hong Bo Lu BRD
 Director/Board Member 53 Mar. 31
Christopher Anzalone CEO
 Chief Executive Officer 54 07-11-30
William Waddill BRD
 Director/Board Member 67 17-12-31
Mauro Ferrari BRD
 Director/Board Member 64 10-08-18
Victoria Vakiener BRD
 Director/Board Member 60 22-05-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 123,896,914 118,333,484 ( 95.51 %) 0 95.51 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
10.26 %
12,705,848 10.26 % 363 M $
The Vanguard Group, Inc.
10.01 %
12,404,050 10.01 % 355 M $
Vanguard Fiduciary Trust Co.
8.614 %
10,672,076 8.614 % 305 M $
STATE STREET CORPORATION
5.509 %
6,825,111 5.509 % 195 M $
Christopher Anzalone
2.998 %
3,715,048 2.998 % 106 M $
Fidelity Management & Research Co. LLC
2.721 %
3,371,268 2.721 % 96 M $
JPMorgan Investment Management, Inc.
2.220 %
2,751,048 2.220 % 79 M $
Geode Capital Management LLC
1.878 %
2,326,876 1.878 % 67 M $
Invesco Advisers, Inc.
1.861 %
2,306,308 1.861 % 66 M $
Credit Suisse International
1.409 %
1,745,342 1.409 % 50 M $

Company contact information

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard Suite 700

91105, Pasadena

+626 304 3400

http://www.arrowheadpharma.com
address Arrowhead Pharmaceuticals, Inc.(ARWR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Arrowhead Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
21.87 USD
Average target price
53.66 USD
Spread / Average Target
+145.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARROWHEAD PHARMACEUTICALS, INC. Stock Arrowhead Pharmaceuticals, Inc.
-28.53% 2.71B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.79% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-11.11% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. Company Arrowhead Pharmaceuticals, Inc.